Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfiuenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized with PIV3 antibodies

Journal of Infectious Diseases

Volumn 179, Issue 6, 1999, Pages 1345-1351

  Durbin, Anna P ^a,b   Cho, Chris J ^a   Elkins, William R ^a   Wyatt, Linda S ^a   Moss, Bernard ^a   Murphy, Brian R ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARAINFLUENZA VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS VACCINE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; IMMUNOGENICITY; NONHUMAN; NOSE SMEAR; PARAINFLUENZA VIRUS; PRIORITY JOURNAL; RHESUS MONKEY; VACCINIA VIRUS; VIRUS IMMUNITY; VIRUS TYPING;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; IMMUNIZATION, PASSIVE; MACACA MULATTA; PARAINFLUENZA VIRUS 3, HUMAN; RESPIRATORY SYSTEM; RESPIROVIRUS INFECTIONS; VACCINATION; VACCINES, SYNTHETIC; VIRAL VACCINES; VIRUS REPLICATION;

EID: 0032990252     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314769     Document Type: Article

References (44)

1. 1. Murphy BR, Prince GA, Collins PL, Van Wyke Coelingh K, Olmsted RA, Spriggs MK, Parrott RH, Kim HW, Brandt CD, Chanock RM. Current approaches to the development or vaccines effective against parainfluenza and respiratory syncytial viruses. Virus Res 1988;11:1-15.
2. 2. Collins PL, Chanock RM, McIntosh K. Parainfluenza Viruses. In: Fields BN, Knipe DM, Howley PM, Chanock RM, Melnick JL, Monath TP, Roizman B, Straus SE, eds. Fields Virology. 3rd ed. Vol. 1. Philadelphia: Lippincott-Raven Publishers, 1996:1205-1243.
3. 3. Crowe JE, Jr., Collins PL, Chanock RM, Murphy BR. Vaccines against respiratory syncytial virus and parainfluenza virus type 3. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, eds. New Generation Vaccines, Second ed. New York: Marcel Dekker, Inc., 1997:711-725.
4. 4. Belshe RB, Karron RA, Newman FK, Anderson EL, Nugent SL, Steinhoff M, Clements ML, Wilson MH, Hall SL, Tierney EL, et al. Evaluation of a live attenuated, cold-adapted parainfluenza virus type 3 vaccine in children. J Clin Microbiol 1992;30:2064-70.
5. 5. Karron RA, Wright PF, Newman FK, Makhene M, Thompson J, Samorodin R, Wilson MH, Anderson EL, Clements ML, Murphy BR, Belshe RB. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children. J Infect Dis 1995;172: 1445-1450.
6. 6. Karron RA, Wright PF, Hall SL, Makhene M, Thompson J, Burns BA, Tollefson S, Steinhoff MC, Wilson MH, Harris DO, Clements ML, Murphy BR. A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children. J Infect Dis 1995;171:1107-1114.
7. 7. Spriggs MK, Murphy BR, Prince GA, Olmsted RA, Collins PL. Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunity. J Virol 1987;61:3416-3423.
8. 8. Spriggs MK, Collins PL, Tierney E, London WT, Murphy BR. Immunization with vaccinia virus recombinants that express the surface glycoproteins of human parainfluenza virus type 3 (PIV3) protects patas monkeys against PIV3 infection. J Virol 1988;62:1293-6.
9. 9. Fenner F, Henderson DA, Arita I, Kezek Z, Ladnyi ID. Smallpox and its eradication. Geneva: World Health Organization, 1988.
10. 10. Redfield RR, Wright DC, James WD, Jones TS, Brown C, Burke DS. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med 1987;316:673-676.
11. 11. Mayr A, Hochstein-Mintzel V, Stickl H. Passage history, properties, and applicability of the attenuated vaccinia virus strain MVA. Infection 1975;3: 6-14.
12. 12. Meyer H, Sutter G, Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 1991;72:1031-1038.
13. 13. Wyatt LS, Shors ST, Murphy BR, Moss B. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine 1996;14:1451-1458.
14. 14. Durbin AP, Wyatt LS, Siew J, Moss B, Murphy BR. The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeys. Vaccine 1998;16:1324-1330.
15. 15. Sutter G, Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci USA 1992;89:10847-10851.
16. 16. Carroll MW, Moss B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 1997;238:198-211.
17. 17. Drexler I, Heller K, Wahren B, Erfle V, Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol 1998;79:347-352.
18. 18. Blanchard TJ, Alcami A, Andrea P, Smith GL. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J Gen Virol 1998;79:1159-1167.
19. 19. Werner GT, Jentzsch U, Metzger E, Simon J. Studies on Poxvirus infections in irradiated animals. Archives of Virology 1980;64:247-256.
20. 20. Stickl H, Hochstein-Mintzel V, Mayr A, Huber HC, Schafer H, Holzner A. MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl). Dtsch Med Wochenschr 1974;99:2386-92.
21. 21. Mayr A, Stickl H, Muller HK, Danner K, Singer H. [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism]. Zentralbl Bakteriol [B] 1978;167:375-90.
22. 22. Galletti R, Beauverger P, Wild TF. Passively administered antibody suppresses the induction of measles virus antibodies by vaccinia-measles recombinant viruses. Vaccine 1995;13:197-201.
23. 23. Murphy BR, Olmsted RA, Collins PL, Chanock RM, Prince GA. Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses. J Virol 1988;62:3907-10.
24. 24. Belshe RB, Hissom FK. Cold adaptation of parainfluenza virus type 3: induction of three phenotypic markers. J Med Virol 1982;10:235-242.
25. 25. Murphy BR, Richman DD, Chalhub EG, Uhlendorf CP, Baron S, Chanock RM. Failure of attenuated temperature-sensitive influenza A (H3N2) virus to induce heterologous interference in humans to parainfluenza type 1 virus. Infect Immun 1975;12:62-68.
26. 26. Hall SL, Stokes A, Tierney EL, London WT, Belshe RB, Newman FC, Murphy BR. Cold-passaged human parainfluenza type 3 viruses contain ts and non-ts mutations leading to attenuation in rhesus monkeys. Virus Res 1992;22:173-184.
27. 27. Clements ML, Belshe RB, King J, Newman F, Westblom TU, Tierney EL, London WT, Murphy BR. Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees. J Clin Microbiol 1991;29:1175-82.
28. 28. Coelingh KJ, Winter CC, Murphy BR, Rice JM, Kimball PC, Olmsted RA, Collins PL. Conserved epitopes on the hemagglutinin-neuraminidase proteins of human and bovine parainfluenza type 3 viruses: nucleotide sequence analysis of variants selected with monoclonal antibodies. J Virol 1986;60:90-6.
29. 29. Katz E, Wolffe EJ, Moss B. The cytoplasmic and transmembrane domains of the vaccinia virus B5R protein target a chimeric human immunodeficiency virus type 1 glycoprotein to the outer envelope of nascent vaccinia virions. J Virol 1997;71:3178-87.
30. 30. Kotwal GJ, Buller RML, Moss B, Stephens E, Compans RW. Analysis of recombinant vaccinia virions for envelope-associated foreign proteins. In: Learner RA, Ginsberg H, Chanock RM, Brown F, eds. Vaccines 89. Modern Approaches to New Vaccines Including Prevention of AIDS. Cold Spring Harbor, N. Y.; Cold Spring Harbor Laboratory, 1989:389-392.
31. 31. Murphy BR. Mucosal immunity to viruses. In: Ogra PL, Mestecky, J., Lamm, M.E., Strober, W., McGhee, J.R., Bienstock, J., ed. Mucosal Immunology. Second ed: Academic Press, Inc, 1999:695-707.
32. 32. Paul WE. Fundamental Immunology. Second ed. New York: Raven Press, 1989:1123.
33. 33. Murphy BR, Alling DW, Snyder MH, Walsh EE, Prince GA, Chanock RM, Hemming VG, Rodriguez WJ, Kim HW, Graham BS, et al. Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection. J Clin Microbiol 1986;24:894-8.
34. 34. Karron RA, Steinhoff MC, Subbarao EK, Wilson MH, Macleod K, Clements ML, Fries LF, Murphy BR. Safety and immunogenicity of a cold-adapted influenza A (HINI) reassortant virus vaccine administered to infants less than six months of age. Pediatr Infect Dis J 1995;14:10-6.
35. 35. Karron RA, Makhene M, Gay K, Wilson MH, Clements ML, Murphy BR. Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two-to six-month-old infants. Pediatr Infect Dis J 1996;15:650-654.
36. 36. Perez-Schael I, Guntinas MJ, Perez M, Pagone V, Rojas AM, Gonzalez R, Cunto W, Hoshino Y, Kapikian AZ. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. N Engl J Med 1997;337:1181-7.
37. 37. Melnick JL. Enteroviruses: Polioviruses, Coxsackieviruses, Echoviruses, and Newer Enteroviruses. In: Fields BN, Knipe DM, Howley PM, Chanock RM, Melnick JL, Monath TP, Roizman B, Straus SE, eds. Fields Virology. Vol. 1. Philadelphia: Lippencott-Raven Publishers, 1996:655-712.
38. 38. Crowe JE, Jr , Bui PT, Siber GR, Elkins WR, Chanock RM, Murphy BR. Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization. Vaccine 1995;13:847-855.
39. 39. Murphy BR, Collins PL, Lawrence L, Zubak J, Chanock RM, Prince GA. Immunosuppression of the antibody response to respiratory syncytial virus (RSV) by pre-existing serum antibodies: partial prevention by topical infection of the respiratory tract with vaccinia virus-RSV recombinants. J Gen Virol 1989;70:2185-90.
40. 40. Bender BS, Rowe CA, Taylor SF, Wyatt LS, Moss B, Small PA, Jr. Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza. J Virol 1996;70:6418-24.
41. 41. Takao SI, Kiyotani K, Sakaguchi T, Fujii Y, Seno M, Yoshida T. Protection of mice from respiratory Sendai virus infections by recombinant vaccinia viruses. J Virol 1997;71:832-838.
42. 42. Mittal SK, Papp Z, Tikoo SK, Baca-Estrada ME, Yoo D, Benko M, Babiuk LA. Induction of systemic and mucosal immune responses in cotton rats immunized with human adenovirus type 5 recombinants expressing the full and truncated forms of bovine herpesvirus type 1 glycoprotein gD. Virology 1996;222:299-309.
43. 43. Fooks AR, Jeevarajah D, Lee J, Warnes A, Niewiesk S, ter Meulen V, Stephenson JR, Clegg JC. Oral or parenteral administration of replication-deficient adenoviruses expressing the measles virus haemagglutinin and fusion proteins: protective immune responses in rodents. J Gen Virol 1998;79:1027-31.
44. 44. Taylor J, Weinberg R, Tartaglia J, Richardson C, Alkhatib G, Briedis D, Appel M, Norton E, Paoletti E. Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins. Virology 1992;187:321-8.